# Corresponding authors: Markus Müller (Markus.Mueller@sib.swiss) and Michal Bassani-Sternberg (Michal.Bassani@chuv.ch) ; Route de la Corniche 9b, , Epalinges, 1066 Switzerland Keywords: de-novo sequencing, HLA, Immunopeptidomics, proteasomal splicing. Runing title: The Contribution of Proteasomal Spliced Peptides to the HLA Ligandome Abbreviations: APPM Antigen processing and presentation machinery HLA Human Leukocyte Antigen HLA-Ip HLA class I binding peptides FDR False discovery rate; FP: false positive AA amino acid LC liquid chromatography MS Mass spectrometry MS/MS Tandem mass spectrometry PSPs Proteasome-spliced peptides DeNovo_spliced Spliced peptides identified by de-novo DeNovo_non-spliced Non-spliced peptides not in UniProt identified by de-novo LM_spliced Spliced peptides identified by Liepe et al.
Introduction
The antigen processing and presentation machinery (APPM) is responsible for the cell surface display of thousands of peptides in the context of the HLA class I (HLA-I) molecules. The proteasome is considered as the main protease that cleaves endogenous proteins. However, in addition to the proteasome, the APPM comprises several other proteases, transporters and chaperones that cooperatively digest the proteins in the cytoplasm, funnel the peptides into the ER, further trim and edit them, load them on newly synthesized HLA-I, and finally direct the stable complexes to the cells' surface (1) . The selective interaction between the HLA-I complex and the peptides is the major factor that defines the presented repertoire and is often represented with binding motifs.
Currently, the only unbiased methodology to comprehensively interrogate the repertoire of the HLA-I binding peptides (HLA-Ip) is based on mass spectrometry (MS). HLA complexes are immunoaffinity-purified from cells in culture or from tissues; the peptides are extracted and subjected to reverse-phase liquid chromatography (LC) coupled online to sensitive MS instruments. The acquired tandem mass spectrometry (MS/MS) data is normally searched against a database of protein sequences. Applying a stringent FDR of 1% using a comparable decoy database leads to the accurate identification of thousands of HLA-Ip. HLA-Ip are mainly 9-11 amino acids (AA) long and usually about 95% of the peptides identified with this methodology fit the consensus binding motifs of the HLA expressed in the samples (2) .
In a recent MS-based HLA-I ligandomics study a novel computational algorithm has predicted that a surprisingly large fraction, up to 30%, of the ligands may be derived from transpeptidation of two noncontiguous fragments of a parental protein that are spliced together within the proteasome (3) . Earlier work showed several cases of such proteasomal spliced HLA-I peptides that were naturally presented and recognized by cytotoxic T cells (4) (5) (6) (7) (8) (9) . Hence, these may be highly interesting therapeutic targets. However, the authors of (3) noticed that unlike the non-spliced peptides, proteasome-spliced peptides (PSPs) had low HLA binding affinities and produced ambiguous binding motifs compared to normal HLA-Ip. HLA loading takes place after the peptides have exited the proteasome and entered the ER, and hence lost the identity of their creation mechanism. Currently, there is no mechanism or biological process that could explain how the APPM can prioritize loading of HLA-I molecules with low affinity PSPs over high-affinity non-spliced peptides.
Understanding the contribution of PSPs to the HLA ligandome is crucial, especially as they may indeed be highly interesting therapeutic targets in many diseases. Here we critically investigated PSPs reported in Liepe et al. (3) and found that most of spectra attributed to them could be assigned with higher scores to normal peptide sequences within the UniProt database of human proteins. We further describe an alternative computational pipeline to estimate the contribution of spliced peptides to the immunopeptidome. Our results suggest that less than 2-4% of the HLA-Ip may be spliced. As opposed to the spliced peptides reported in (3), these peptides fit well to the relevant HLA binding motifs.
Experimental Procedures
HLA ligandomic data. We selected previously published MS HLA-Ip datasets of exceptionally high coverage representing a variety of binding specificities (Supplemental Table 1 ). MS raw files of HLA-Ip isolated from two melanoma tissues, Mel15 (16 raw files) and Mel16 (12 raw files) (10), RA957 B cell line (4 raw files) (11) and Fibroblast (Fib) cells (4 raw files) (2) were downloaded from the PRIDE repository (12) dataset PXD004894, PXD005231 and PXD000394, respectively. One of the four raw MS files of the Fib cells (20130504_EXQ3_MiBa_SA_Fib-2.raw) was also used by Liepe et al. More details about these datasets can be found on PRIDE and the respective manuscripts.
Data processing. If not otherwise mentioned, data were processed with the R statistical scripting language (version 3.3.2) (https://www.r-project.org/).
Experimental design and statistical rationale:
Identification of HLA-Ip using PEAKS. Raw files were analyzed with the de-novo sequencing software PEAKS Studio 8.0 (13) . General parameters were set to "Ion Source": ESI (nano-spray), "Fragmentation Mode": high energy CID (y and b ions), "MS Scan Mode" and "MS/MS Scan Mode": FT-ICR/Orbitrap. The different PEAKS modules were used in the following order with their default parameters while special parameters are indicated in parenthesis: 1. DATA REFINE, 2. DENOVO ("Parent Mass Error Tolerance": 10 ppm, "Fragment Mass Error Tolerance": 0.02 Da, "Enzyme": None), 3. PEAKS ("Parent Mass Error Tolerance": 10 ppm, "Fragment Mass Error Tolerance": 0.02 Da, "Variable Modifications": Oxidation (M) 15.99, "Database": Homo_sapiens_UP000005640_9606), 4. PEAKS PTM ("Parent Mass Error Tolerance": 10 ppm, "Fragment Mass Error Tolerance": 0.02 Da, "Enzyme": None, "Database": Homo_sapiens_UP000005640_9606), 5. SPIDER ("Variable Modifications": Oxidation (M) 15.99, "Fragment ion tolerance": 0.02). All peptides with -10LogP > 15 were considered having a match with a human protein from UniProt (Homo_sapiens_UP000005640_9606). Peptides with a -10LogP ≤15 (FDR around 1.5%) and a ALC% ≥ 15 were considered as "de novo only peptides". Peptides with mutations and modifications were ignored.
For the subsequent analysis we merely kept "de novo only peptides" with a length between 8 and 25 AA.
For each PSM we kept the highest ranked match with a local confidence score over 80 for every amino acid position if not otherwise mentioned. In order to simplify association of peptides with their corresponding HLA alleles, peptides containing PTMs were removed.
Identification of possible spliced-peptides using TagPep. We checked whether the filtered list of sequences from the "de-novo only peptides", which did not match any UniProt sequence, could be spliced fragments from UniProt (Homo_sapiens_UP000005640_9606) proteins. We applied an in-house software tool TagPep, which uses the index strategy described for fetchGWI (14) adapted for AAs instead of nucleotides. TagPep first matches the whole peptide sequence to the database. If there is no complete hit, it looks for hits allowing for one splicing event, where both spliced fragments are from the same protein (Supplemental Data 1). We excluded trans-spliced peptides where the fragments stem from two different proteins for three reasons. First, all spliced peptides reported in (15) are concatenated fragments from the same protein. Second, the huge number of trans-spliced may lead to strongly increased false positive rates in subsequent bioinformatics analysis, and third, for trans-splicing to happen the two source proteins need to be present in the same proteasome at the same time, which is unlikely to happen on a large scale. The spliced fragments can lie anywhere in the protein, but their sequences cannot overlap. We only considered TagPep matches if the splice gap, i.e. the minimal distance between the two spliced fragments, was less than 20 AA. It has been argued that the splice gap in truly existing spliced peptides is usually lower than 20 AAs (16) . This distance threshold was used in Liepe et al. (3) . We named the resulting set of spliced peptides as DeNovo_spliced. The remaining peptides in the PEAKS "de-novo only peptides" list that are not present in DeNovo_spliced were named DeNovo_non-spliced.
Of note, PEAKS de-novo assigns the mass 113.08406 by default as Leucine, and therefore the TagPep results may bias against identification of Isoleucine containing sequences. These isobaric amino acids make up 10% of all amino acids. However, even if 50% of the Leucine/Isoleucine PEAKS assignments are misplaced, this would lead to a wrong TagPep match in roughly 5-10% of all spliced peptides (assuming one or two Leucine/Isoleucine per peptide); therefore, will not significantly change our main results. Table 2 ) corresponding to peptides identified from Fib data were mixed and desalted on a C-18 spin column (Harvard Apparatus, 74-4101) and measured at a total amount of 10 and 20 pmol. Synthetic peptides were separated by a nanoflow HPLC (Proxeon Biosystems, Thermo Fisher Scientific, Odense) and coupled on-line to a Q Exactive HF mass spectrometer (Thermo Fisher Scientific, Bremen) with a nanoelectrospray ion source (Proxeon Biosystems). We packed a 20 cm long, 75 μm inner diameter column with ReproSil-Pur C18-AQ 1.9 μm resin (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) in buffer A (0.5% acetic acid). Peptides were eluted with a linear gradient of 2-30% buffer B (80% ACN and 0.5% acetic acid) at a flow rate of 250 nl/min over 90 min. Data was acquired using a data-dependent 'top 10' method. We acquired full scan MS spectra at a resolution of 70,000 at 200 m/z with an Auto gain control (AGC) target value of 3e6 ions. Ten most abundant ions were sequentially isolated, activated by Higher-energy collisional dissociation and accumulated to an AGC target value of 1e5 with a maximum injection time of 120 ms. In case of unassigned precursor ion charge states, or charge states of four and above, no fragmentation was performed. The peptide match option was disabled. MS/MS resolution was set to 17,500 at 200 m/z. Selected ions form fragmentation were dynamically excluded from further selection for 20 seconds. We employed the MaxQuant settings mentioned above for synthetic peptides identification. to LM_spliced peptides that MaxQuant identified instead as UniProt peptides. This selection was not biased and was not based on prior knowledge, which would favor MaxQuant. We synthesized the 21 pairs of peptide sequences and the three LM_spliced peptide sequences and analyzed them by MS as mentioned above. For visual inspection we printed the endogenous and synthetic spectra to pdf files. For each of the 21 pairs, we calculated the similarity between the spectrum of the eluted peptide from Fib, annotated as
Confirmation of identification of spliced peptides using MaxQuant and Comet. We employed the

LC-MS/MS analyses and identification of selected synthetic HLA-Ip. Synthetic peptides (PEPotech Heavy grade 3, Thermo Fisher Scientific) (listed in Supplemental
Comparison of MS/MS annotations of endogenous
LM_spliced and the spectrum of the synthetic LM_spliced peptide. We also calculated the similarity between the spectrum of the eluted peptide from Fib annotated as a UniProt peptide, and the spectrum of the synthetic Uniprot peptide. Similarly, we calculated the similarity between the three spectra of the identically identified spliced sequences and the spectra of their synthetic counterparts. The similarity was computed by the cosine score (correlation coefficient; value between 0 and 1, where a value of 0 corresponds to spectra with no peaks in common and a value of 1 to identical spectra) (19) . The MzJava class library (20) was used to read the .mgf spectrum files and to calculate the similarity.
Binding affinity prediction and clustering of peptides. We used the NetMHCpan (21) to predict binding affinity of 8-14 mer peptides to the respective HLA alleles expressed in the sample and assigned them based on maximum affinity. Hits with a rank <2% were considered as binders. Gibbscluster-1.1 (22) was run independently for each list of peptides identified from the different samples, with the default settings except that the number of clusters was tested between 1 and 6, a trash cluster was enabled and alignment was disabled (23). The MixMHCp tool (http://mixmhcp.org/) was used to cluster the peptides with default settings (11, 24). and GibbsCluster (22) to identify the consensus binding motifs within the lists of 9-mer HLA-Ip in a fully unsupervised way (i.e., without predicting their binding affinity). Four dominant motifs corresponding to the HLA-A and HLA-B allotypes expressed in the Fib cells were identified for the LM_UniProt peptides with both methods, whereas the motifs found in the LM_spliced peptides were much less specific and did not match the known alleles (Figure 1 A) . Furthermore, we observed a different length distribution of the LM_spliced and LM_UniProt peptides (Figure 1 B) . LM_Uniprot peptides followed the expected peptide length distributions of HLA-I alleles with the majority of peptides of length 9, while LM_spliced peptides unexpectedly displayed the same amount of 9-and 10-mers. We obtain similar results for the fraction of (Figure 1 C) . Since all searches were performed at a spectrum level FDR of 1%, the differences should not be larger than 2% and these values are within this range.
Results
Predicted spliced peptides from Liepe et al. do not fit well to the consensus binding motifs
However, for the group of common MS/MS scans, which matched to LM_spliced peptides in (3) (Figure 1 C) . Therefore, these results do not depend on the particular choice of search tool, but it seems that the PSMs assigned as LM_spliced peptides were more ambiguous compared to UniProt peptides, possibly because many LM_spliced peptides bear strong similarity to UniProt peptides.
To increase the coverage of possible spliced peptides, we searched three additional raw files of HLA-Ip derived from the same Fib cells. In total, MaxQuant identified 202 (17.5 %) and Comet 213 (18.5%) peptides as LM_spliced sequences (Supplemental Table 3 ). Compared to PSMs assigned as UniProt, 
Synthetic Peptide Searches
We selected 21 MS/MS scans from the Fib sample, where Liepe et al. matched a spliced peptide and MaxQuant matched a UniProt peptide. This selection was not biased to favor MaxQuant results, but we chose spectra that appeared to be typical for the group of spectra that produced conflicting results. For each of the 21 scans we synthesized two peptides: one according to the LM-spliced identification and one for the UniProt alternative. We compared the MS/MS spectra of the synthetic peptides to the spectra of the endogenous peptides. As an example, we show the endogenous and synthetic spectra of the 
Alternative pipeline to estimate the contribution of spliced peptides to the HLA-peptidome
In order to shed more light on the detection of PSPs by MS, we implemented a different computational pipeline (Figure 3 A) , which is based on de-novo sequencing (25) . This pipeline proceeds in three steps: 1) de-novo sequencing of MS/MS spectra to retrieve only de-novo sequences not found in UniProt. 2) flagging de-novo sequences by the alignment tool TagPep as DeNovo_spliced and DeNovo_non-spliced peptides.
3) adding the candidate DeNovo_spliced and DeNovo_non-spliced sequences to UniProt fasta protein/peptide reference database files and searching them with MaxQuant and Comet at FDR of 1% with variable modifications. The idea behind the last step is to match each MS/MS spectrum to either DeNovo_spliced, DeNovo_non-spliced or Uniprot. Importantly, this computational pipeline bypasses the step of matching MS/MS spectra to a huge database of potential spliced peptides.
We used the PEAKS tool (13) for de-novo sequencing of the immunopeptidomics MS/MS spectra from four different biological samples (see Experimental procedures section for more details). First, we estimated the error present in the PEAKS de-novo sequences. We compared spectra matches assigned by both PEAKS and MaxQuant to UniProt peptides as a function of the PEAKS local confidence score. For a local confidence score higher than 80 the peptides assigned to the spectra by both PEAKS and MaxQuant agreed in 80% of the cases (Supplemental Figure 5 A) . We can accept this level of performance, since in our computational approach the proposed peptides are subsequently filtered by the consecutive MaxQuant or Comet analysis at FDR of 1%. Comparison for the UniProt sequences showed that PEAKS could identify about half the peptides as compared to MaxQuant at the given thresholds (Supplemental Figure 5 B ). This is expected since de-novo sequencing requires searching a large search space of all AA combinations. Furthermore, we observed that PEAKS is not optimized for non-tryptic peptides (see below).
Next we checked whether the identified de-novo sequences that did not match a UniProt sequence could be PSPs by an in-house alignment tool called TagPep (14) . TagPep is a very fast alignment tool employing efficient indexing. TagPep first matches the whole de-novo peptide sequence to the protein database and if there is no hit it tries to match it with one splicing event (Supplemental Data 1). The number of TagPep matches per de-novo sequence depends on the allowed splice gap between the spliced protein fragments.
Having no restrictions on the splice gap, 20% of random amino acid sequences of length 8-11 could be matched as a spliced peptide to the human proteome database. Figure 3 B shows that more than half of the de-novo_spliced sequences produce a unique TagPep match with a splice gap of less than 20 AA, whereas 90% of the sequences have three matches or less. Only about 10% of the sequences have more than 3 matches and have many possible explanations. Furthermore, we estimated that including the second best PSMs identified by PEAKS de-novo with a local confidence score >80 would increase the number of de novo sequences by less than 10% (Supplemental Figure 5 C Table 4 ). Most of the PSPs found by our pipeline were predicted to bind to the HLA-molecules (Figure 3 C) . Moreover, in both the PSPs found by our pipeline as well as the DeNovo_non-spliced, we could see evidences of the expected binding motifs (Supplemental Figure 6) , even if the number of peptides is significantly smaller than for the predicted spliced peptides of Liepe (3) . The differences between the binding specificities of DeNovo_spliced, DeNovo_non-spliced and UniProt peptides, as seen in case of the HLA-B27:05 in Mel15, are most likely related to a bias against identification of HLA-B27 peptides in PEAKS (Supplemental Figure 7) , which has difficulty identifying such non-tryptic peptides.
Compared to the UniProt peptides, the DeNovo_spliced peptides found by our pipeline have a slightly higher absolute mass error and lower delta score, but they have very similar score and charge distribution.
However, compared to the spliced peptides found by Liepe et al, the DeNovo_spliced peptides have better match characteristics: lower absolute mass error, higher Andromeda scores and delta scores, higher number of matching ions and less singly charged PSMs (Supplemental Figure 2 A-F) . 13) . Ten of the DeNovo_non-spliced sequences, which were identified by our pipeline, could also be explained by a peptide encompassing such variants. These results highlight the needs to carefully evaluate spliced peptides identified by MS/MS and make sure that they do not have a different, potentially simpler explanation.
Sequence variants and spliced peptide conflicts
Characterization of the splicing events
Lastly, we found that in many DeNovo_spliced peptides, identified by both MaxQuant and Comet, the splicing position is at the N-and C-termini (Figure 4 A) in contrast to the LM_spliced peptides (Figure 4 B) , which have more uniformly distributed splicing positions. The distribution of MaxQuant delta scores as a function of splice position indicates that certain splice positions may on average be more ambiguous than others (Figure 4 C) . On the other hand, it could also be possible that single AA abundant in the proteasome or during sample processing could be attached to the peptide termini. This effect is known as transpeptidation and was observed in tryptic samples (26) .
Discussion
Examples of proteasomal-spliced peptides have been reported and some of them were shown to be immunogenic (4-9, 16, 27-29) . A true estimation of the contribution of spliced peptides to the global immunopeptidome is critical in order to fundamentally understand the biological pathways involved.
Consequently, advanced computational and experimental tools must be developed and benchmarked to facilitate their confident identification. In a typical peptidomics setting, we match MS/MS spectra against a large set of theoretical peptide spectra, most of which are not present in the sample. This endeavor produces two types of PSMs: true matches and false positives. False positives are very common especially for spliced peptides since these peptides can produce similar MS/MS spectra to UniProt peptides with similar match scores. For example, the potential spliced peptide KRI-PLPTKK only differs from its UniProt counterpart RIKPLPTKK by a permutation of the first three AA. When using a very large proteasomal spliced peptide database there is an elevated chance that a potential spliced peptide will have a very similar spectrum to the UniProt peptide and produce a higher match score. Furthermore, if a spectrum has no match in the UniProt database (e.g. when it originates from a modified peptide, sequence variant or contaminant not considered in the search) it may still match a spliced peptide with a score that is significant.
The error in the multiple testing of MS/MS searches is controlled by using decoy database in order to calculate the FDR (31, 32) . One assumption behind this target-decoy approach is that the scores of the decoy peptides reflect the scores of wrongly assigned PSMs. When using decoys for spliced peptides, their similarity with the UniProt sequences may be lost and one would have to carefully evaluate whether the assumption mentioned above still holds. If it does not hold, the target-decoy approach might underestimate the FDR and lead to many false positives especially for large spliced peptide databases.
Trans-splicing of fragments derived from two source proteins that happen to be present in the same proteasome complex at the same time, is unlikely to happen on a large scale, hence we focused our study on cis-splicing events. To overcome biases related to searching all possible cis-splice peptides, we developed an alternative workflow based on de-novo sequencing and subsequent verification with multiple search tools including the most prevalent amino acid modifications and sequence variants detected by exome sequencing. We found that 1-2% of the high quality PSMs originate from potential proteasome cis-spliced peptides. These peptides fitted the HLA consensus binding motifs and had good spectrum match properties. Given that our de-novo sequencing approach finds about half of the peptides compared to a UniProt sequence search, we can say that the maximal amount of spliced peptide candidates is 2-4%. However, MS/MS based approaches cannot ultimately determine the creation mechanism of these peptides and different sequence interpretations may also be possible. For example, a significant number of detected HLA-Ip originates from transcripts, which do not fall into a UniProt protein coding region (33) , and these non-canonical peptides could be misinterpreted as PSPs. Other ambiguities may be due to post-translational or chemical peptide modifications not considered in the search. Overall, our results present an upper bound for the proportion of cis-spliced peptides, and the true contribution of such PSPs to the HLA-I ligandome may be much smaller.
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